In this podcast (10.15), Medicom’s correspondents discuss 6 presentations from the recent European Academy of Neurology’s Annual Congress, held 21-24 June 2025, in Helsinki, Finland.
Topics covered are: Why it stands out: First-ever reports of dramatic recovery in treatment-refractory autoimmune neuropathies using autologous CD19 CAR T cells.
Quote highlight: “One patient was able to perform squats and pull-ups... the other could walk independently over 200 meters.”
2. Virus-Specific T Cells for Treating PML
Why it stands out: A life-saving, novel immunotherapy option for an often fatal disease in immunocompromised patients.
Quote highlight: “Twelve-month survival rates were significantly higher compared with historical controls.”
3. GLP-1 Receptor Agonists Reduce Migraine Burden, Independent of Weight Loss
Why it stands out: Surprising migraine benefits from a diabetes/obesity drug suggest a new therapeutic pathway.
Quote highlight: “The beneficial effect could not be attributed to weight loss.”
4. Early Add-On Treatment in Myasthenia Gravis
Why it stands out: Demonstrates that timing of escalation to biologic treatment strongly influences outcomes.
Quote highlight: “Early escalation was associated with faster and deeper MG-ADL improvements.”
5. ChatGPT in Diagnosing Polyneuropathies
Why it stands out: Evaluates real-world diagnostic performance of GPT-4 compared to specialists—relevant, timely, and controversial.
Quote highlight: “GPT outperformed non-specialists and improved their diagnostic accuracy.”
6. Adaptive Deep Brain Stimulation for Parkinson’s Disease
Why it stands out: Explores cutting-edge DBS technology that could personalise Parkinson’s therapy in real time.
Quote highlight: “Stimulation must adapt to patients’ needs throughout the day; adaptive DBS may be the way forward.”
Enjoy listening!
Copyright ©2025 Medicom Medical Publishers
Posted on
Table of Contents: EAN 2025
Featured articles
Letter from the Editor
Lecanemab in AD: not a paradigm shift, but a small step forward
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Neuropathies
Is ChatGPT helpful in diagnosing polyneuropathies?
Riliprubart could be a new treatment option for CIDP
CAR T cell therapy shows promise in severe autoimmune neuropathies
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com